Jun. 18 at 5:28 PM
Attached is a graph of
$NVCR share price since 7/1/2024.
NVCR surged in 12/2024 after a successful Phase 3 read in pancreatic. NVCR's TTF devices were first approved in FY2011 (I think) & do not generate traditional pharma type gross margins. Nonetheless, NVCR did
$600MM in FY2024 sales. With the recent label expansion into NSCLC & the pancreatic data read, analysts forecast NVCR revenues to grow to over
$1B by FY2029.
NVCR trades at 2.1X FY2028 analyst consensus revenue estimates per Seeking Alpha. Fintel reports a higher estimate.
$BPMC published its 14D9 yesterday that included Year 4 M&A multiples paid in BPMC peer M&A transactions.
NVCR may not be an appropriate peer for BPMC.
FWIW
$EXEL trades at 3.5X FY2028 consensus. EXEL's first therapy was also approved 11/29/2012.
$SNDX trades at 1.6X FY28 consensus (2 FDA approved therapies).
This is not investment advice.
$LEGN